Cancer screening reduced targeted cancer mortality without significantly increasing deaths from other causes. Meta-analysis of 17 studies found a 0.2% increase in off-target mortality rates in ...
In average-risk individuals, ColoSense demonstrated 93% sensitivity for detecting colorectal cancer (CRC) and 45% sensitivity for detecting advanced adenomas (AA). The CRC-PREVENT study evaluated more ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback